Molecular biological diagnostics of KRAS and BRAF mutations in patients with colorectal cancer - Laboratory experience;Molekulárně biologická diagnostika mutací genu KRAS a BRAF u pacientů s kolorektálním karcinomem - Zkušenosti laboratorního pracoviště

Klinicka Onkologie

Volumn 26, Issue 1, 2013, Pages 25-30

  Robešová, Blanka ^a   Bajerova M ^a   Vasikova A ^a   Ostrizkova L ^b   Hausnerova J ^b   Kyclova J ^b   Pospisilova S ^a   Mayer, J ^a   Dvorakova D ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

BRAF; Colorectal neoplasms; KRAS; Molecular diagnostics; Molecular targeted therapy; Monoclonal antibodies

Indexed keywords

B RAF KINASE; K RAS PROTEIN;

ARTICLE; CANCER CELL; CODON; COLORECTAL CANCER; DIAGNOSTIC KIT; GENE MUTATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; METASTASIS; MOLECULAR DIAGNOSTICS; POLYMERASE CHAIN REACTION;

EID: 84874762857     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: 10.14735/amko201325     Document Type: Article

References (28)

1. www.svod.cz. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice [online], cit. 2012-9-10. Dostupný z WWW: http/www.svod.cz.
2. Haggar FA, Boushey RP. Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors. Clin Colon Rectal Surg 2009; 22(4). 191-197.
3. Monzon FA, Ogino S, Hammond ME et al. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 2009; 133(10): 1600-1606.
4. Lièvre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66(8): 3992-3995.
5. Modrá kniha České onkologické společnosti. Platnost od 1.8. 2012. Brno, Česká onkologická společnost ČLS JEP 2012.
6. Lièvre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26(3): 374-379. (Pubitemid 351171687)
7. Siena S, Sartore-Bianchi A, Di Nicolantonio F et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy inmetastatic colorectal cancer. J Natl Cancer Inst 2009; 101(19): 1308-1324.
8. van Krieken JH, Jung A, Kirchner T et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008; 453(5): 417-431.
9. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26(10): 1626-1634.
10. Patil DT, Fraser CR, Plesec TP. KRAS testing and its importance in colorectal cancer. Curr Oncol Rep 2010; 12(3): 160-167.
11. Stintzing S, Heinemann v, Moosmann N et al. The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status. Dtsch Arztebl Int 2009; 106(12): 202-206.
12. Sun L, Zhang Q, Luan H et al. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. J Exp Clin Cancer Res 2011; 17; 30: 30.
13. Pellegata NS, Sessa F, Renault B et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994; 54(6): 1556-1560. (Pubitemid 24106422)
14. Bando I, Cillero L, Sanz-Ortega J et al. Study of KRAS new predictive marker in a clinical laboratory Clin Transl Oncol 2012; 14(12): 937-942.
15. Laurent-Puig P, Cayre A, Manceau G et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27(35): 5924-5930.
16. Van Cutsem E, Dicato M, Arber N et al. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann Oncol 2010; 21(Suppl 6):vi1-vi10.
17. Simi L, Pratesi N, Vignoli M et al. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 2008; 130(2): 247-253.
18. Richman SD, Seymour MT, Chambers P et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27(35): 5931-5937.
19. Edkins S, O'Meara S, Parker A et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 2006; 5(8): 928-932.
20. Neumann J, Zeindl-Eberhart E, Kirchner T et al. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 2009; 205(12): 858-862.
21. Artale S, Sartore-Bianchi A, Veronese SM et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26(25): 4217.
22. Velho S, Oliveira C Seruca R KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases. J Clin Oncol 2009; 27(1): 158-159.
23. Krypuy M, Newnham GM, Thomas DM et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 2006, 6:295.
24. Benlloch S, Payá A, Alenda C et al. Detection of BRAF V600E mutation in colorectal cancer: Comparison of automatic sequencing and Real-Time chemistry metodology. J Mol Diagn 2006; 8(5): 540-543. (Pubitemid 44774151)
25. Willmore-Payne C, Holden JA, Tripp S et al. Human malignant melanoma detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 2005; 36(5): 486-493. (Pubitemid 40776001)
26. Gallegos Ruiz MI, Floor K, Rijmen F et al. EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. Cell Oncol 2007; 29(3): 257-264. (Pubitemid 46855706)
27. Loupakis F, Pollina L, Stasi I et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009; 27(16): 2622-2629.
28. Knijn N, Mekenkamp LJ, Klomp M et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011; 104(6): 1020-1026.